Inflammatory Bowel Diseases
|
0.600 |
Biomarker
|
group |
BEFREE |
Tumour necrosis factor α inhibitors (anti-TNFα) are the main therapy for moderate to severe inflammatory bowel disease (IBD) in children.
|
31535405 |
2020 |
Inflammatory Bowel Diseases
|
0.600 |
Biomarker
|
group |
BEFREE |
Treatment with tumor necrosis factor antagonists increased steadily for patients with CD (43.4% of all patients in Brazil were treated in 2014) but less so for patients with UC (4.5% of all patients were treated in 2014).Surgery for IBD decreased with time.
|
31252191 |
2020 |
Inflammatory Bowel Diseases
|
0.600 |
GeneticVariation
|
group |
BEFREE |
A total of 2701 IBD patients under current or former treatment with TNF-α inhibitors were identified in an IBD registry covering the period 1994-2018.
|
31466830 |
2020 |
Inflammatory Bowel Diseases
|
0.600 |
Biomarker
|
group |
BEFREE |
Effects of Tumor Necrosis Factor Alpha Inhibitors on Lymph Node and Ileocecal Mucosa-Associated Lymphoid Tissue Architecture in Patients With Inflammatory Bowel Disease.
|
31362580 |
2020 |
Inflammatory Bowel Diseases
|
0.600 |
Biomarker
|
group |
BEFREE |
A Population-Based Study of Combination vs Monotherapy of Anti-TNF in Persons With IBD.
|
31340002 |
2020 |
Inflammatory Bowel Diseases
|
0.600 |
Biomarker
|
group |
BEFREE |
Adequate serum drug levels of tumor necrosis factor-alpha inhibitors (anti-TNF) have been shown to improve outcomes in patients with inflammatory bowel disease (IBD).
|
31503216 |
2020 |
Inflammatory Bowel Diseases
|
0.600 |
Biomarker
|
group |
BEFREE |
Combination therapies for IBD that include TNF antagonists, especially with corticosteroids, are associated with a higher risk of serious infection, whereas monotherapy with an immunosuppressive agent is associated with a lower risk, compared with monotherapy with a TNF antagonist.
|
30876964 |
2020 |
Inflammatory Bowel Diseases
|
0.600 |
Biomarker
|
group |
BEFREE |
Trends of Utilization of Tumor Necrosis Factor Antagonists in Children With Inflammatory Bowel Disease: A Canadian Population-Based Study.
|
31323083 |
2020 |
Inflammatory Bowel Diseases
|
0.600 |
Biomarker
|
group |
BEFREE |
Human genetic, tissue expression, proteomics, transcriptomics, and nonclinical studies implicate tumor necrosis factor α-like ligand 1A (TL1A) as a novel target in inflammatory bowel disease (IBD).
|
31758576 |
2020 |
Inflammatory Bowel Diseases
|
0.600 |
Biomarker
|
group |
BEFREE |
Tumor necrosis factor (TNF)-α is a major proinflammatory cytokine that plays a key role in inflammatory bowel disease (IBD).
|
31586441 |
2020 |
Inflammatory Bowel Diseases
|
0.600 |
Biomarker
|
group |
BEFREE |
The efficacy of antitumour necrosis factor (TNF)-α biologics has validated the role of inflammatory cytokines notably TNF-α in the exacerbation and perpetuation of IBD.
|
30407662 |
2019 |
Inflammatory Bowel Diseases
|
0.600 |
Biomarker
|
group |
BEFREE |
There was a positive correlation between IgA and IgG on CD but not UC, as well as between IgA and TNF in total IBD patients.
|
30884988 |
2019 |
Inflammatory Bowel Diseases
|
0.600 |
Biomarker
|
group |
BEFREE |
Is There a Risk of Lymphoma Associated With Anti-tumor Necrosis Factor Drugs in Patients With Inflammatory Bowel Disease? A Systematic Review of Observational Studies.
|
30941038 |
2019 |
Inflammatory Bowel Diseases
|
0.600 |
Biomarker
|
group |
BEFREE |
In recent years, more molecules, both biologically and chemically synthetized, have been developed as potential therapeutic options for IBD that target different molecular pathways aside from TNF blockade, and which have been proposed as targets for novel drugs.
|
31316377 |
2019 |
Inflammatory Bowel Diseases
|
0.600 |
Biomarker
|
group |
BEFREE |
Anti-tumor necrosis factor-alpha (anti-TNF-α) therapy alters the gut microbiota in many diseases, including inflammatory bowel disease.
|
31556231 |
2019 |
Inflammatory Bowel Diseases
|
0.600 |
Biomarker
|
group |
BEFREE |
We therefore performed a comprehensive analysis of vedolizumab-induced alterations in mucosal and systemic immunity in patients with inflammatory bowel disease (IBD), using anti-inflammatory therapy with the TNFα antibody infliximab as control.
|
29730603 |
2019 |
Inflammatory Bowel Diseases
|
0.600 |
Biomarker
|
group |
BEFREE |
TNF-like ligand 1 A (TL1A) and death receptor 3 (DR3) are a ligand-receptor pair involved in the pathogenesis of inflammatory bowel disease.
|
31358760 |
2019 |
Inflammatory Bowel Diseases
|
0.600 |
Biomarker
|
group |
BEFREE |
Sex Differences in Response to TNF-Inhibiting Drugs in Patients With Spondyloarthropathies or Inflammatory Bowel Diseases.
|
30745872 |
2019 |
Inflammatory Bowel Diseases
|
0.600 |
Biomarker
|
group |
BEFREE |
Corticosteroids and Thiopurines, But Not Tumor Necrosis Factor Antagonists, are Associated With Cytomegalovirus Reactivation in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis.
|
27875356 |
2019 |
Inflammatory Bowel Diseases
|
0.600 |
Biomarker
|
group |
BEFREE |
Since production of TNFα is a feature of IBD relevant to therapies, we sought to determine whether B cells in GALT or the CD27<sup>-</sup>IgD<sup>-</sup> subset in particular could contribute to pathology by secretion of TNFα or IL-10.
|
30891036 |
2019 |
Inflammatory Bowel Diseases
|
0.600 |
Biomarker
|
group |
BEFREE |
Polymorphisms in the NFkB, TNF-alpha, IL-1beta, and IL-18 pathways are associated with response to anti-TNF therapy in Danish patients with inflammatory bowel disease.
|
30811631 |
2019 |
Inflammatory Bowel Diseases
|
0.600 |
Biomarker
|
group |
BEFREE |
We performed a systematic review of changes in fecal and colon microbiomes of patients with inflammatory bowel diseases (IBD) receiving treatment with monoclonal antibodies against tumor necrosis factor (TNF), integrins, or cytokines.
|
31526845 |
2019 |
Inflammatory Bowel Diseases
|
0.600 |
Biomarker
|
group |
BEFREE |
The clinical success of biologics that inhibit TNF (Tumor Necrosis Factor) in inflammatory bowel diseases (IBD), psoriasis and rheumatoid arthritis (RA) has clearly established a pathogenic role for this cytokine in these inflammatory disorders.
|
31457011 |
2019 |
Inflammatory Bowel Diseases
|
0.600 |
Biomarker
|
group |
BEFREE |
Tumor necrosis factor alpha (TNF-α) is usually regarded as a potential target for inflammatory bowel disease therapy.
|
30714345 |
2019 |
Inflammatory Bowel Diseases
|
0.600 |
Biomarker
|
group |
BEFREE |
Although KEGG showed inflammatory bowel disease in the E. coli group, the KEGG pathway analysis showed that these DEGs were mainly involved in the tumor necrosis factor signaling pathway, fructose metabolism, and mannose metabolism in both <i>S. aureus</i>- and <i>E. coli</i>-induced sepsis.
|
31093495 |
2019 |